Danny N. Khalil

4.3k total citations · 1 hit paper
40 papers, 1.6k citations indexed

About

Danny N. Khalil is a scholar working on Oncology, Hepatology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Danny N. Khalil has authored 40 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Oncology, 11 papers in Hepatology and 10 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Danny N. Khalil's work include Cancer Immunotherapy and Biomarkers (17 papers), CAR-T cell therapy research (13 papers) and Pancreatic and Hepatic Oncology Research (12 papers). Danny N. Khalil is often cited by papers focused on Cancer Immunotherapy and Biomarkers (17 papers), CAR-T cell therapy research (13 papers) and Pancreatic and Hepatic Oncology Research (12 papers). Danny N. Khalil collaborates with scholars based in United States, Italy and Lebanon. Danny N. Khalil's co-authors include Jedd D. Wolchok, Eric L. Smith, Renier J. Brentjens, Ghassan K. Abou‐Alfa, James J. Harding, Imane El Dika, Taha Merghoub, Eileen M. O’Reilly, Luís Felipe Campesato and Luca Fabris and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer.

In The Last Decade

Danny N. Khalil

37 papers receiving 1.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The future of cancer treatment: immunomodulation, CARs and combination immunotherapy

2016 924 citations Danny N. Khalil, Eric L. Smith et al. Nature Reviews Clinical Oncology profile →

Peers

Countries citing papers authored by Danny N. Khalil

Since Specialization

Citations

This map shows the geographic impact of Danny N. Khalil's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Danny N. Khalil with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Danny N. Khalil more than expected).

Fields of papers citing papers by Danny N. Khalil

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Danny N. Khalil. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Danny N. Khalil. The network helps show where Danny N. Khalil may publish in the future.

Co-authorship network of co-authors of Danny N. Khalil

This figure shows the co-authorship network connecting the top 25 collaborators of Danny N. Khalil. A scholar is included among the top collaborators of Danny N. Khalil based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Danny N. Khalil. Danny N. Khalil is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Molecular and clinical determinants of targeted therapy (TT) outcomes in biliary tract cancer (BTC): Analysis of a prospectively maintained next generation sequencing (NGS) biorepository. 2025 ·Journal of Clinical Oncology ·(unknown), Henry Walch, Pranita Atri, (unknown), (unknown), Danny N. Khalil, Wungki Park, Randy Yeh, Richard Kinh Gian, Olca Baştürk, Jinru Shia, Michael F. Berger, Eileen M. O’Reilly, William R. Jarnagin, Nikolaus Schultz, Mithat Gönen, David B. Solit, Ghassan K. Abou‐Alfa, Walid K. Chatila, James J. Harding	0
2	Phase 2/3 study of livmoniplimab in combination with budigalimab in patients with locally advanced or metastatic hepatocellular carcinoma. 2024 ·Journal of Clinical Oncology ·Ghassan K. Abou‐Alfa, Mohamed Bouattour, Ann‐Lii Cheng, Farshid Dayyani, Danny N. Khalil, Daneng Li, Chih‐Yi Liao, Carlos López, Lorenza Rimassa, Jonathan Deutsch, (unknown), Maulik Patel, Juki Ng, Anne S. Henkel, Cristiano Ferlini	4
3	Salvage Ablative Radiotherapy for Isolated Local Recurrence of Pancreatic Adenocarcinoma following Definitive Surgery 2024 ·Journal of Clinical Medicine ·Edward Christopher Dee, Victor Ng, Eileen M. O’Reilly, Alice C. Wei, Stephanie Lobaugh, Anna M. Varghese, (unknown), Paul B. Romesser, Abraham J. Wu, Carla Hajj, John Cuaron, Danny N. Khalil, Wungki Park, Kenneth H. Yu, Zhigang Zhang, Jeffrey A. Drebin, William R. Jarnagin, Christopher H. Crane, Marsha Reyngold	0
4	First-in-human clinical outcomes with NG-350A, an anti-CD40 expressing tumor-selective vector designed to remodel immunosuppressive tumor microenvironments 2024 ·Journal for ImmunoTherapy of Cancer ·Aung Naing, Danny N. Khalil, Oliver Rosen, (unknown), Tom Lillie, (unknown), Andrea Stacey, Matthew C. Thomas, Lee S. Rosen	5
5	P-266 Outcomes in advanced hepatocellular carcinoma (HCC) patients (pts) treated with immune checkpoint inhibitors (ICI) 2023 ·Annals of Oncology ·(unknown), Marinela Capanu, Fergus Keane, Danny N. Khalil, Jinru Shia, Richard Kinh Gian, Joanne F. Chou, Henry Walch, Imane El Dika, Amin Yaqubie, David B. Solit, Michael F. Berger, Eileen M. O’Reilly, James J. Harding, Ghassan K. Abou‐Alfa	1
6	A tumor-selective adenoviral vector platform induces transient antiphospholipid antibodies, without increased risk of thrombosis, in phase 1 clinical studies 2023 ·Investigational New Drugs ·Danny N. Khalil, (unknown), Lee S. Rosen, Tom Lillie, Andrea Stacey, (unknown), Gerald A. Soff	7
7	Clinical outcomes for IDH1 mutant biliary tract cancer (BTC) treated with contemporary systemic therapy. 2023 ·Journal of Clinical Oncology ·(unknown), (unknown), (unknown), Fergus Keane, Wungki Park, Imane H. El Dika, Danny N. Khalil, Jinru Shia, Carlie Sigel, Chaitanya Bandlamudi, Michael F. Berger, David B. Solit, Eileen M. O’Reilly, Ghassan K. Abou‐Alfa, James J. Harding	0
8	Durable Response after Olaparib Treatment for Perihilar Cholangiocarcinoma with Germline BRCA2 Mutation 2023 ·Oncology Research and Treatment ·Bruno Almeida Costa, Paulino Tallón de Lara, Wungki Park, Fergus Keane, James J. Harding, Danny N. Khalil	4
9	Radiation and Immune Checkpoint Inhibitors: Combination Therapy for Treatment of Hepatocellular Carcinoma 2023 ·International Journal of Molecular Sciences ·(unknown), (unknown), Danny N. Khalil, Hassan Azhari, William R. Jarnagin, Ghassan K. Abou‐Alfa, James J. Harding, (unknown), Jennifer Ma, Maria El Homsi, Marsha Reyngold, Christopher H. Crane, Carla Hajj	11
10	Phase II trial of maximal ablative irradiation because of encasement (MAIBE) for patients with potentially resectable locally advanced pancreatic cancer. 2023 ·Journal of Clinical Oncology ·Marsha Reyngold, (unknown), Eileen M. O’Reilly, Michael I. D’Angelica, Jeffrey A. Drebin, Kevin C. Soares, T. Peter Kingham, Vinod P. Balachandran, Anna M. Varghese, Wungki Park, Danny N. Khalil, Kenneth H. Yu, (unknown), John Cuaron, Carla Hajj, Paul B. Romesser, Abraham J. Wu, Zhigang Zhang, William R. Jarnagin, Christopher H. Crane	2
11	Stereotactic ablative radiation for pancreatic cancer on a 1.5 Telsa magnetic resonance-linac system 2022 ·Physics and Imaging in Radiation Oncology ·Kathryn R. Tringale, Neelam Tyagi, Marsha Reyngold, Paul B. Romesser, Abraham J. Wu, Eileen M. O’Reilly, Anna M. Varghese, (unknown), Danny N. Khalil, Wungki Park, Kenneth H. Yu, Christopher H. Crane	15
12	Rational development of combination therapies for biliary tract cancers 2022 ·Journal of Hepatology ·James J. Harding, Danny N. Khalil, Luca Fabris, Ghassan K. Abou‐Alfa	40
13	Association of Ablative Radiation Therapy With Survival Among Patients With Inoperable Pancreatic Cancer 2021 ·JAMA Oncology ·Marsha Reyngold, Eileen M. O’Reilly, Anna M. Varghese, Megan Fiasconaro, (unknown), Paul B. Romesser, Abraham J. Wu, Carla Hajj, John Cuaron, Richard Tuli, Lara Hilal, Danny N. Khalil, Wungki Park, Ellen Yorke, Zhigang Zhang, Kenneth H. Yu, Christopher H. Crane	106
14	Targeted APC Activation in Cancer Immunotherapy to Enhance the Abscopal Effect 2019 ·Frontiers in Immunology ·(unknown), Luís Felipe Campesato, Taha Merghoub, Danny N. Khalil	46
15	Biomarkers: What Role Do They Play (If Any) for Diagnosis, Prognosis and Tumor Response Prediction for Hepatocellular Carcinoma? 2019 ·Digestive Diseases and Sciences ·James J. Harding, Danny N. Khalil, Ghassan K. Abou‐Alfa	27
16	Immune checkpoint inhibitors for hepatocellular carcinoma 2019 ·Cancer ·Imane El Dika, Danny N. Khalil, Ghassan K. Abou‐Alfa	76
17	An Open-Label, Dose–Escalation Phase I Study of Anti-TYRP1 Monoclonal Antibody IMC-20D7S for Patients with Relapsed or Refractory Melanoma 2016 ·Clinical Cancer Research ·Danny N. Khalil, Michael A. Postow, Nageatte Ibrahim, Dale L. Ludwig, Jan Cosaert, (unknown), Shande Tang, Dmitri Grebennik, John Kauh, Heinz‐Josef Lenz, Keith T. Flaherty, F. Stephen Hodi, Donald P. Lawrence, Jedd D. Wolchok	19
18	The future of cancer treatment: immunomodulation, CARs and combination immunotherapy breakdown → 2016 ·Nature Reviews Clinical Oncology ·Danny N. Khalil, Eric L. Smith, Renier J. Brentjens, Jedd D. Wolchok	924
19	Treatments for Noncutaneous Melanoma 2014 ·Hematology/Oncology Clinics of North America ·Danny N. Khalil, Richard D. Carvajal	7
20	Why does Oncotype DX recurrence score reduce adjuvant chemotherapy use? 2012 ·Breast Cancer Research and Treatment ·Jeffrey Schneider, Danny N. Khalil	14

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact